Clinical significance of the phosphorylation of MAPK and protein expression of cyclin D1 in human osteosarcoma tissues

Wu,Jian; Cui,Lei‑Lei; Yuan,Jun; Wang,Yuan; Song,Shu

doi:10.3892/mmr.2017.6224

Clinical significance of the phosphorylation of MAPK and protein expression of cyclin D1 in human osteosarcoma tissues

Authors:
- Jian Wu
- Lei‑Lei Cui
- Jun Yuan
- Yuan Wang
- Shu Song
View Affiliations

Affiliations: Department of Laboratory Medicine, The First People's Hospital of Yancheng City, Yancheng, Jiangsu 224005, P.R. China, Department of Laboratory Medicine, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China, Pathological Science Laboratory, The First People's Hospital of Yancheng City, Yancheng, Jiangsu 224005, P.R. China
Published online on: February 21, 2017 https://doi.org/10.3892/mmr.2017.6224
Pages: 2303-2307

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the significance of the phosphorylation of mitogen-activated protein kinase (MAPK) and the protein expression of cyclin D1 in human osteosarcoma tissues. Human osteosarcoma tissue samples were collected from 30 patients, benign bone tumor samples were collected from 30 patients, and normal bone tissues were collected from 10 individuals as controls. Immunohistochemistry was performed to measure the levels of phosphorylated (p)-MAPK and cyclin D1 protein in cases of human osteosarcoma. The results showed that the positive rates of MAPK and cyclin D1 in osteosarcoma were 86.67% (26/30) and 73.00% (22/30), respectively. The positive staining rates of MAPK and cyclin D1 in benign bone tumor tissues were 10.00% (3/30) and 3.30% (1/30), respectively. The positive rate in the normal bone tissues was 0% (0/30), which was significantly lower, compared with that of the cancerous bone tissue. The positive rates of MAPK and cyclin D1 in osteosarcoma were increased (P<0.05), and the expression of cyclin D1 and p‑MAPK were positively correlated. The phosphorylation of MAPK may be important in the development of osteosarcoma, and the overactivation of MAPK may induce high expression of cyclin D1 and induce tumor cells to proliferate continuously.

View Figures

View References

1	Huang J, Liu K, Song D, Ding M, Wang J, Jin Q and Ni J: Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells. Cancer Sci. 107:242–249. 2016. View Article : Google Scholar : PubMed/NCBI
2	Li YS, Deng ZH, Zeng C and Lei GH: JNK pathway in osteosarcoma: Pathogenesis and therapeutics. J Recept Signal Transduct Res. 36:465–470. 2016. View Article : Google Scholar : PubMed/NCBI
3	Chakravarthi PS, Kattimani VS, Prasad LK and Satish PR: Juxtacortical osteosarcoma of the mandible: Challenges in diagnosis and management. Natl J Maxillofac Surg. 6:127–131. 2015. View Article : Google Scholar : PubMed/NCBI
4	Zhou W, Zhu Y, Chen S, Xu R and Wang K: Fibroblast growth factor receptor 1 promotes MG63 cell proliferation and is associated with increased expression of cyclin-dependent kinase 1 in osteosarcoma. Mol Med Rep. 13:713–719. 2016.PubMed/NCBI
5	Yang J, Cheng D, Zhou S, Zhu B, Hu T and Yang Q: Overexpression of X-Box Binding Protein 1 (XBP1) Correlates to Poor Prognosis and Up-Regulation of PI3K/mTOR in Human Osteosarcoma. Int J Mol Sci. 16:28635–28646. 2015. View Article : Google Scholar : PubMed/NCBI
6	Shao Y, Wang C, Hong Z and Chen Y: Inhibition of p38 mitogen-activated protein kinase signaling reduces multidrug transporter activity and anti-epileptic drug resistance in refractory epileptic rats. J Neurochem. 136:1096–1105. 2016. View Article : Google Scholar : PubMed/NCBI
7	Zhang J, Liu Q, Fang Z, Hu X, Huang F, Tang L and Zhou S: Hypoxia induces the proliferation of endothelial progenitor cells via upregulation of Apelin/APLNR/MAPK signaling. Mol Med Rep. 13:1801–1806. 2016.PubMed/NCBI
8	Xu W, Yang Z, Zhou SF and Lu N: Posttranslational regulation of phosphatase and tensin homolog (PTEN) and its functional impact on cancer behaviors. Drug Des Devel Ther. 8:1745–1751. 2014. View Article : Google Scholar : PubMed/NCBI
9	Liang N, Zhang C, Dill P, Panasyuk G, Pion D, Koka V, Gallazzini M, Olson EN, Lam H, Henske EP, et al: Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J Exp Med. 211:2249–2263. 2014. View Article : Google Scholar : PubMed/NCBI
10	Wu J, Lu WY and Cui LL: Clinical significance of STAT3 and MARK Phosphorylation, and the protein expression of cyclin D1 in skin squamous cell carcinoma tissues. Mol Med Rep. 12:8129–8134. 2015.PubMed/NCBI
11	Talbot JJ, Song X, Wang X, Rinschen MM, Doerr N, LaRiviere WB, Schermer B, Pei YP, Torres VE and Weimbs T: The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation. J Am Soc Nephrol. 25:1737–1748. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhang YH, Li B, Shen L, Shen Y and Chen XD: The role and clinical significance of YES-associated protein 1 in human osteosarcoma. Int J Immunopathol Pharmacol. 26:157–167. 2013. View Article : Google Scholar : PubMed/NCBI
13	Zheng ZP, Yan Y, Xia J, Zhang S, Wang M, Chen J and Xu Y: A phenylacetaldehyde-flavonoid adduct, 8-C-(E-phenylethenyl)- norartocarpetin, exhibits intrinsic apoptosis andMAPK pathways-related anticancer potential on HepG2, SMMC-7721 and QGY-7703. Food Chem. 197:1085–1092. 2016. View Article : Google Scholar : PubMed/NCBI
14	Cursons J, Angel CE, Hurley DG, Print CG, Dunbar PR, Jacobs MD and Crampin EJ: Spatially transformed fluorescence image data for ERK-MAPK and selected proteins within human epidermis. Gigascience. 4:632015. View Article : Google Scholar : PubMed/NCBI
15	Beauvais S, Drevelle O, Lauzon MA, Daviau A and Faucheux N: Modulation of MAPK signalling by immobilized adhesive peptides: Effect on stem cell response to BMP-9-derived peptides. Acta Biomater. 31:241–251. 2016. View Article : Google Scholar : PubMed/NCBI
16	Dreyer JH, Hauck F, Barros MH and Niedobitek G: pRb and CyclinD1 Complement p16 as Immunohistochemical Surrogate Markers of HPV Infection in Head and Neck Cancer. Appl Immunohistochem Mol Morphol. 2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
17	Wu J, Lv S, An J and Lu C: Pre-miR-149 rs71428439 polymorphism is associated with increased cancer risk and AKT1/cyclinD1 signaling in hepatocellular carcinoma. Int J Clin Exp Med. 8:13628–13633. 2015.PubMed/NCBI
18	Yang Y, Zhao LH, Huang B, Wang RY, Yuan SX, Tao QF, Xu Y, Sun HY, Lin C and Zhou WP: Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling. Mol Carcinog. 54:1584–1595. 2015. View Article : Google Scholar : PubMed/NCBI
19	Shi QQ, Zuo GW, Feng ZQ, Zhao LC, Luo L, You ZM, Li DY, Xia J, Li J and Chen DL: Effect of trichostatin a on anti HepG2 liver carcinoma cells: Inhibition of HDAC activity and activation of Wnt/β-catenin signaling. Asian Pac J Cancer Prev. 15:7849–7855. 2014. View Article : Google Scholar : PubMed/NCBI
20	Wang X, Liu H, Wang X, Zeng Z, Xie LQ, Sun ZG and Wei MX: Preventive effect of Actinidia valvata Dunn extract on N-methyl-N'-nitro-N-nitrosoguanidine-induced gastrointestinal cancer in rats. Asian Pac J Cancer Prev. 15:6363–6377. 2014. View Article : Google Scholar : PubMed/NCBI
21	Gopalakrishnan N, Saravanakumar M, Madankumar P, Thiyagu M and Devaraj H: Colocalization of β-catenin with Notch intracellular domain in colon cancer: A possible role of Notch1 signaling in activation of CyclinD1-mediated cell proliferation. Mol Cell Biochem. 396:281–293. 2014. View Article : Google Scholar : PubMed/NCBI